TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation ...

New capabilities mark continued momentum as company advances discovery research applications and accelerates the global growth of its spatial biology business Takara Bio USA, Inc. (“Takara Bio USA”), ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the Stocks to Buy Under $10 with High Potential. On January 15, Soumit Roy from JonesTrading reiterated a Buy rating on the stock and raised the price target ...

Fintel reports that on January 26, 2026, B of A Securities initiated coverage of Belite Bio, Inc - Depositary Receipt (NasdaqCM:BLTE) with a Buy recommendation. Analyst Price Forecast Suggests 14.84% ...

Climb Bio appointed Dr. Perrin Wilson as Chief Business Officer to strengthen its leadership in developing immune-mediated disease treatments. Climb Bio, Inc. has announced the appointment of Dr.

INmune Bio Inc. (NASDAQ:INMB) stock surged by 24.72% in after-hours trading on Friday. The company announced a novel selective soluble TNF inhibitor, which is likely to have influenced the stock’s ...

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of ...

Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...

Korro Bio, Inc. ( KRRO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST ...